Vertex’s CF Combo Treatment Shows Some Potential

Interim results from a Phase II study show the combination of Vertex Pharmaceuticals’ VX-770 and VX-809 met primary endpoints in treating the defective protein that causes cystic fibrosis (CF) but still may be disappointing in the short-term, an analyst says.
Clinical Trials Advisor